Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life

References

• Tejwani V, Nowacki AS, Fye E, Sanders C, Stoller JK. The impact of delayed diagnosis of alpha-1 antitrypsin deficiency: the association between diagnostic delay and worsened clinical status. Respir Care. 2019. doi:10.4187/respcare.06555.
   PubMed Web of Science ®Google Scholar
• Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61(6):461–467.7828337
   PubMed Web of Science ®Google Scholar
• Zacherle E, Noone JM, Runken MC, Blanchette CM. Health care cost and utilization associated with alpha-1 antitrypsin deficiency among a cohort of medicare beneficiaries with COPD. Value Health. 2015;18(7):A664. doi:10.1016/j.jval.2015.09.2419
   Web of Science ®Google Scholar
• Cassileth BR, Lusk EJ, Strouse TB, et al. Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med. 1984;311(8):506–511. doi:10.1056/NEJM198408233110805.6749208
   PubMed Web of Science ®Google Scholar
• Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611–2620. doi:10.1056/NEJMoa1003955.21190455
   PubMed Web of Science ®Google Scholar
• Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–1211. doi:10.1378/chest.127.4.1205.15821196
   PubMed Web of Science ®Google Scholar
• Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung. 2009;187(2):128–135. doi:10.1007/s00408-009-9135-9.19198940
   PubMed Web of Science ®Google Scholar
• Cleland JA, Lee AJ, Hall S. Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients. Fam Pract. 2007;24(3):217–223. doi:10.1093/fampra/cmm009.17504776
   PubMed Web of Science ®Google Scholar
• Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest. 2002;122(5):1633–1637. doi:10.1378/chest.122.5.163312426264
   PubMed Web of Science ®Google Scholar
• Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J. 2005;26(3):414–419. doi:10.1183/09031936.05.00078504.16135721
   PubMed Web of Science ®Google Scholar
• Dowson CA, Town GI, Frampton C, Mulder RT. Psychopathology and illness beliefs influence COPD self-management. J Psychosom Res. 2004;56(3):333–340. doi:10.1016/S0022-3999(03)00040-0.15046971
   PubMed Web of Science ®Google Scholar
• Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med. 2009;103(10):1572–1579. doi:10.1016/j.rmed.2008.11.021.19560330
   PubMed Web of Science ®Google Scholar
• Stallberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. doi:10.1038/s41533-018-0101-y.30202023
   PubMed Web of Science ®Google Scholar
• Hoth KF, Wamboldt FS, Strand M, et al. Prospective impact of illness uncertainty on outcomes in chronic lung disease. Health Psychol. 2013;32(11):1170–1174. doi:10.1037/a0032721.23772888
   PubMed Web of Science ®Google Scholar
• Worthington AK, Parrott RL, Smith RA. Spirituality, illness unpredictability, and math anxiety effects on negative affect and affect-management coping for individuals diagnosed with alpha-1 antitrypsin deficiency. Health Commun. 2018;33(4):363–371. doi:10.1080/10410236.2016.1266576.28059573
   PubMed Web of Science ®Google Scholar
• Mullins CD, Huang X, Merchant S, Stoller JK. Alpha one foundation research network registry I. The direct medical costs of alpha(1)-antitrypsin deficiency. Chest. 2001;119(3):745–752. doi:10.1378/chest.119.3.745.11243952
   PubMed Web of Science ®Google Scholar
• Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989–1994. doi:10.1378/chest.128.4.1989.16236846
   PubMed Web of Science ®Google Scholar
• Chiuchiolo MJ, Crystal RG. Gene therapy for alpha-1 antitrypsin deficiency lung disease. Ann Am Thorac Soc. 2016;13(Suppl 4):S352–S69. doi:10.1513/AnnalsATS.201506-344KV.27564673
   PubMed Web of Science ®Google Scholar
• Sveger T, Thelin T. A future for neonatal alpha1-antitrypsin screening? Acta Paediatr. 2000;89(3):259–261.10772268
   PubMed Web of Science ®Google Scholar
• Thelin T, McNeil TF, Aspegren-Jansson E, Sveger T. Psychological consequences of neonatal screening for alpha 1-antitrypsin deficiency. Parental reactions to the first news of their infants’ deficiency. Acta Paediatr Scand. 1985;74(5):787–793.3876683
   PubMed Web of Science ®Google Scholar
• McNeil TF, Sveger T, Thelin T. Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience. Thorax. 1988;43(7):505–507. doi:10.1136/thx.43.7.505.3264944
   PubMed Web of Science ®Google Scholar
• McNeil TF, Thelin T, Aspegren-Jansson E, Sveger T, Harty B. Psychological factors in cost-benefit analysis of somatic prevention. A study of the psychological effects of neonatal screening for alpha 1-antitrypsin deficiency. Acta Paediatr Scand. 1985;74(3):427–432.3923778
   PubMed Web of Science ®Google Scholar
• Sveger T, Thelin T, McNeil TF. Neonatal alpha1-antitrypsin screening: parents’ views and reactions 20 years after the identification of the deficiency state. Acta Paediatr. 1999;88(3):315–318.10229044
   PubMed Web of Science ®Google Scholar
• Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr. 1997;86(1):37–40.9116423
   PubMed Web of Science ®Google Scholar
• Holm KE, Plaufcan MR, Ford DW, et al. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. J Behav Med. 2014;37(4):654–663. doi:10.1007/s10865-013-9516-7.23645147
   PubMed Web of Science ®Google Scholar
• Campos MA, Alazemi S, Zhang G, et al. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med. 2009;103(10):1532–1539. doi:10.1016/j.rmed.2009.04.008.19464158
   PubMed Web of Science ®Google Scholar
• Holm KE, Borson S, Sandhaus RA, et al. Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD. 2013;10(2):226–234. doi:10.3109/15412555.2012.719049.23547634
   PubMedGoogle Scholar
• Angermann CE, Ertl G. Depression, anxiety, and cognitive impairment: comorbid mental health disorders in heart failure. Curr Heart Fail Rep. 2018;15(6):398–410. doi:10.1007/s11897-018-0414-8.30402659
   PubMedGoogle Scholar
• Dickson MR, Carter CL, Carpenter MJ, et al. Barriers to genetic testing among persons at risk for alpha-1 antitrypsin deficiency. Genet Test. 2008;12(4):501–505. doi:10.1089/gte.2008.0028.19072562
   PubMedGoogle Scholar
• Coors ME, Levinson AH, Huitt GA. Anxiety related to genetic testing for alpha-1 antitrypsin deficiency and cystic fibrosis in COPD and/or bronchiectasis patients. Community Genet. 2008;11(3):135–140. doi:10.1159/000113875.18376109
   PubMedGoogle Scholar
• Vozoris NT, Wang X, Austin PC, et al. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. Eur Respir J. 2018;52(1). doi:10.1183/13993003.00475-2018.
   Web of Science ®Google Scholar
• O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56(9):692–699. doi:10.1016/j.jacc.2010.03.068.20723799
   PubMed Web of Science ®Google Scholar
• Angermann CE, Gelbrich G, Stork S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. 2016;315(24):2683–2693. doi:10.1001/jama.2016.7635.27367876
   PubMed Web of Science ®Google Scholar